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ABSTRACT  
 
Influenza A, B and C viruses (IAV, IBV, ICV) circulate globally and infect humans, with 
IAV/IBV causing most severe disease. While CD8+ T-cells confer cross-protection against 
different IAV strains, CD8+ T-cell responses to IBV/ICV are understudied. We dissected the 
CD8+T-cell cross-reactome against influenza viruses and provided the first evidence of CD8+ 
T-cell cross-reactivity across IAV, IBV and ICV. Using immunopeptidomics, we identified 
immunodominant CD8+ T-cell epitopes from IBV, protective in mice, and found prominent 
memory CD8+ T-cells towards both universal and influenza type-specific epitopes in blood 
and lungs of healthy humans, with lung-derived CD8+ T-cells displaying a tissue-resident 
phenotype. Importantly, effector CD38+Ki67+CD8+ T-cells against novel epitopes were 
readily detected in IAV- and IBV-infected pediatric and adult patients. Our study introduces 
a new paradigm, whereby CD8+ T-cells confer unprecedented cross-reactivity across all 
influenza viruses, a key finding for designing universal vaccines. 
 
 
 
 
 
 
  
	 4	
 
INTRODUCTION 
Although 2018 marks the 100th anniversary of the catastrophic Spanish influenza 
pandemic, influenza viruses remain a constant, global health threat. Three types (genera) of 
influenza viruses infect humans: type A (or influenza A virus - IAV), type B (IBV) and type 
C (ICV). Two subtypes of IAV (A/H3N2 and A/H1N1pdm09) and two lineages of IBV 
(B/Yamagata/16/88-like and B/Victoria/2/87-like) co-circulate annually causing seasonal 
epidemics of mild, severe or fatal respiratory disease, while ICV causes severe disease in 
children1, 2, 3, 4, 5. Antigenically novel IAVs, generated by reassortment of the segmented 
genome and derived from animal reservoirs (aquatic birds and water fowl) or intermediate 
animal hosts (domesticated birds and swine) can also infect humans with high rates of 
morbidity and mortality1. When novel IAVs acquire the ability of sustained human-to-human 
transmissions, devastating influenza pandemics can occur. 
The search for a long-lasting universal, broadly protective vaccine against influenza 
viruses is ongoing. Immune protection against influenza viruses is mainly mediated by 
adaptive humoral and cellular responses, although innate T cells also contribute to immune 
responses1, 2. Antibodies and B cells, induced by seasonal inactivated influenza vaccine (IIV), 
typically elicit strain-specific immunity by targeting the highly variable head domain of the 
surface glycoprotein hemagglutinin (HA). While these antibodies can provide neutralizing 
immunity, the constant antigenic drift of the HA protein makes them poor targets for broad 
cross-protection. Broadly cross-reactive antibodies predominantly targeted against the 
conserved stem of the HA molecule or at neuraminidase (NA)6, can provide heterosubtypic 
cross-reactivity across either multiple IAV subtypes7 or across IBVs, but not heterotypic 
cross-reactivity across IAVs and IBVs, with the reported exception of one rare antibody 
clone (CR9114)8. Conversely, cytotoxic CD8+ T cells provide cross-protection across either 
seasonal IAVs9, 10 or IBVs11 as well as pandemic12, 13, 14, 15 and avian16, 17, 18 IAVs by 
recognizing highly conserved virus-derived peptides presented by Major Histocompatibility 
Complex class 1 (MHC-I) glycoproteins (Human Leukocyte Antigens (HLAs) in humans) on 
the surface of infected cells. To date, 195 CD8+ T cell epitopes restricted by 24 different 
HLA alleles have been identified for IAVs, 7 epitopes (restricted by 2 HLAs; HLA-A*0201 
or HLA-B*0801) for IBV and no T cell epitopes are currently known for ICV (Immune 
Epitope Database accessed on the 2nd Jan 2018). Following recognition of the peptide/MHC-I 
complex (epitope), CD8+ T cells kill virally-infected cells and release anti-viral cytokines 
(IFNγ and TNF). The breadth of CD8+ T cell cross-reactivity across antigenically-novel 
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viruses renders them promising targets for a universal vaccine. However, the current IIV 
formulation does not boost memory CD8+ T cells19. Thus, novel vaccine formulations are 
needed to harness the potential of such cross-protective CD8+ T cells.  
The establishment of universal immune memory against influenza viruses requires 
prior knowledge of conserved antigenic regions to facilitate immunogen design and 
assessment of the immune response. While antibodies can be firstly isolated from serum and 
then mapped to epitopes, identification of antigen-specific CD8+ T cells requires prior 
knowledge of the antigenic epitope, including both the peptide and the restricting HLA. 
While antibodies can be firstly isolated from serum and then used to map the epitopes, 
identification of antigen-specific CD8+ T cells requires prior knowledge of the antigenic 
epitope, including both the peptide and the restricting HLA. Such knowledge can then be 
used to inform the antigenic composition of T cell-based vaccines, so they can be formulated 
as individual peptides, long epitope-rich peptides, mosaic peptides or even whole protein 
antigens to focus the immune response towards conserved and protective epitopes. Here, we 
defined the CD8+ T cell cross-reactome against influenza A, B and C viruses and identified 
the antigenic specificity of IBV CD8+ T cells using immunopeptidomics20, 21. We 
demonstrated that CD8+ T cells can confer a previously unrecognized, broadly heterotypic 
cross-reactivity and characterized these responses in depth. Our data provide novel insights 
into universal CD8+ T cell targets across IAV, IBV and ICV types and show that combining 
universal CD8+ T cell peptide targets with B cell-based vaccines might lead to a broadly-
protective influenza vaccine that does not require annual reformulation. 
 
RESULTS 
Universally cross-reactive CD8
+
 T cell epitopes across IAV, IBV and ICV subtypes 
To investigate the breadth of CD8+ T cell cross-reactivity across IAV, IBV and ICV 
viruses, we first assessed the conservation of previously identified IAV-specific CD8+ T cell 
epitopes across IAV, IBV and ICV types (Fig. 1a, Supplementary Fig. 1), as IAV-specific 
CD8+ T cells have been the main research focus to date. Our conservation analysis of 
>67,000 influenza segment sequences identified 31 conserved epitopes (with >70% amino 
acid identity) across IAV and IBV as well as 8 epitopes across all IAV, IBV and ICV 
influenza types (Supplementary Table S1). Based on the prevalence of HLA-restricting 
molecules in the population and the nature of mutations within the peptide variants, we 
selected 9 epitopes across both HLA-A (HLA-A*01:01, HLA-A*02:01 and HLA-
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A*03:01/A*11:01/*31:01/A*68:02) and HLA-B (HLA-B*07:02, HLA-B*44:02 and HLA-
B*37:01) alleles (Fig. 1b) for further investigation.  
To determine CD8+ T cell immunogenicity towards these epitopes, we probed 
memory CD8+ T cells within PBMCs obtained from healthy adults using in vitro peptide 
expansion and measured IFN-γ production after peptide re-stimulation. Our data indicate that 
three (A1/PB1591 n=3, A2/PB1413 n=5, B37/NP338 n=3) out of the nine conserved CD8
+ T cell 
epitopes recalled robust memory CD8+ T cell responses across multiple donors (Fig. 1c). 
These conserved CD8+ T cell peptides (PB1591-599, PB1413-421 and NP338-345) are restricted by 
three prominent HLA molecules (HLA-A*01:01, HLA-A*02:01 and HLA-B*37:01, 
respectively), providing broad global coverage as ~54% of the population carry at least one 
of these three alleles, although some geographic regions would be underrepresented.  
 Strikingly, the NMLSTVLGV PB1413-421 peptide in IAV (positioned as PB1414-422 in 
IBV and ICV; referred to as PB1413 hereafter) was universally (>98% of sequences) 
conserved (average identity >99.9%) across IAV, IBV and ICV, but not in influenza D 
viruses, where a L7F mutation was found, or other genera of the Orthomyxoviridae family 
like Infectious Salmon Anemia virus, Wellfleet Bay virus or Thogoto virus (Fig. 1d). The 
PB1413-421 peptide has previously been reported as an IAV epitope
22, 23, that is share in 
sequence with IBV 24, however, CD8+ T cell cross-reactivity has not been shown. To 
demonstrate the ability of A2/PB1413-specific CD8
+ T cells to confer cross-reactivity across 
IAV, IBV and ICV subtypes, PBMCs obtained from HLA-A*0201-expressing donors were 
stimulated in vitro with autologous PBMCs infected with either IAV, IBV or ICV, followed 
by measuring A2/PB1413
+CD8+ T cell responses by IFN-γ on d10 (n=5) (Fig. 1e). In contrast 
to minimal IFN-γ production towards PB1413 peptide directly ex vivo (Fig.  1e), 10-day 
culture with IAV-, IBV- or ICV-infected targets markedly increased the magnitude of 
A2/PB1413-specific CD8
+ T cells (Fig. 1e), due to expansion of A2/PB1413
+CD8+ T cells 
towards all three IAV, IBV and ICV types. Our data thus provide the first evidence that 
memory A2/PB1413
+CD8+ T cells are activated following stimulation with either IAV-, IBV- 
and ICV-infected targets, introducing a new paradigm that CD8+ T cells can exhibit universal 
cross-reactivity across IAV, IBV and ICV, and hence have a much broader cross-reactivity 
potential than previously thought.  
Analysis of the remaining two conserved and immunogenic peptides (PB1591-599 and 
NP338-345 in IAV, BPB1590-598 and BNP394-401 in IBV) revealed variations at one or two amino 
acids (S2A and L8I for PB1591 and F1Y within NP338) between IAV and IBV viruses, and a 
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lack of conservation in ICV (Fig. 1b). In vitro expansion with either IAV- or IBV-derived 
peptides showed unidirectional cross-reactivity, with IAV-expanded CD8+ T cells 
recognizing both IAV- and IBV-derived peptides, although the latter to a lesser extent. 
However, the IBV variants could not expand CD8+ T cells directed at the cognate peptides, 
suggesting that the mutations may render these variants less immunogenic (Fig. 1f-g). 
Collectively, our data demonstrate that human CD8+ T cells can confer heterotypic 
cross-reactivity across IAV and IBV and ICV types. As the above findings are only based on 
the currently known IAV-derived epitopes and thus are mainly limited to IAV peptides 
presented by well-characterized HLA class-I molecules, such universal cross-reactivity might 
be broader than defined here. Furthermore, our data suggest a need for identification of novel 
CD8+ T cell epitopes recognizing both IAV- and IBV-derived peptides restricted by a broad 
range of HLAs represented across different ethnicities. 
 
Identification of novel HLA-A*02:01-restricted IBV epitopes by immunopeptidomics 
As there is a general lack of CD8+ T cell epitopes known for the clinically-relevant and 
understudied IBVs, we sought to address this knowledge gap. We embarked on the 
identification program of novel CD8+ T cell epitopes derived from IBV viruses and presented 
by HLA-A*02:01, due to the high global prevalence of this allele. We utilized an 
immunopeptidomics approach to define peptides naturally processed and presented on the 
surface of IBV-infected cells. EBV-transformed B lymphoblastoid class I-reduced (C1R) 
cells lines stably expressing high levels of the HLA-A*02:01 molecule were used, together 
with the parental C1R cells, expressing background levels HLA-B*35:01 and HLA-
C*04:0125, to exclude peptides derived from these HLA molecules. Infection of C1R cells 
with the B/Malaysia resulted in high infection rates (~70% BNP+ cells) and high cell viability 
(~93%) (Supplementary Fig. 2a). Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analysis of peptides isolated from HLA-A*02:01 molecules revealed predominantly 
9-mer (n=1490), followed by 11-mer (n=695) and 10-mer (n=589) peptides (Fig. 2a-b, 
Supplementary Fig. 2b). These peptides mainly exhibited the canonical anchor residues of 
HLA-A*02:01 ligands (Leucine (L) at P2 and L or Valine (V) at the C-terminus26 (Fig. 2b). 
Length distributions were similar for human peptides from uninfected cells and human and 
viral peptides from infected cells (Supplementary Fig. 2c). Analyses from two independent 
experiments yielded a total of 73 potential HLA-A*02:01-presented IBV-derived peptides, 
with ~64% overlap between the experiments (Supplementary Table S2). The IBV-derived 
peptides mainly originated from hemagglutinin (BHA) (22.3%), followed by BNP (16.4%) 
	 8	
and BM1 (11.9%), with all IBV proteins contributing to the HLA-A*02:01 
immunopeptidome, except from BM2 and NB (Fig. 2d). In contrast, numerous peptides 
derived from BM2 were identified at high confidence in the analysis of peptides presented by 
the HLA class II of C1R cells (Supplementary Fig. 2d, Supplementary Table S2). Of these 
73 HLA-A2 binding IBV peptides, 67 were synthesized for further investigation.  
 
Prominence of novel IBV A2/BHA543- and A2/BNS1266-specific CD8
+
 T cells IBV 
epitopes in healthy humans  
 To dissect IBV-specific CD8+ T cell responses towards the 67 LC/MS-identified IBV-
peptides, we firstly probed the memory CD8+ T cell pools in HLA-A*02:01-expressing 
individuals. We randomly assigned the peptides in 6 pools of 10-12 peptides, avoiding 
overlapping peptides in the same pool (Supplementary Table S2). We established CD8+ T 
cell lines specific for each of the 6 peptide pools, and then re-stimulated cells with the 
cognate pool in an IFNγ/ΤΝF ICS assay (Fig. 2fg). CD8+ T cell responses were 
predominantly targeted towards pool 2 (80% of donors responding, n=11), with smaller 
responses detected in some donors for pools 1, 3, 4 and 6 (Fig. 2f, Supplementary Fig. 3a). 
Dissection of pool 2 into individual peptides verified A2/BHA543-551 as the prominent epitope 
amongst HLA-A*0201+ donors (n=6) (Fig. 2h). Numerically smaller responses towards 
A2/BHA538-551, A2/NS1266-274, A2/BNS1264-274 and BM1132-140 were also detected in some 
donors (Supplementary Fig. 3b). To validate these responses independently of the peptide 
pools, we established CD8+ T cell lines towards individual immunogenic peptides (Fig. 2ij). 
CD8+ T cell responses to A2/BHA543-551 were of the greatest magnitude (median 7.35% of 
CD8+ T cells; n=6) and more frequent amongst donors (6/6) than the A2/NS1266-274, 
A2/BNS1264-274 and A2/BM1132-140 (0.035% and 0.025% of CD8
+ T cells, respectively), each 
found in a single donor (Fig. 2j, Supplementary Fig. 2b). Thus, our thorough in vivo and in 
vitro analysis identified 5 novel peptides recognized by CD8+ T cells in complex with the 
HLA-A*02:01 molecule, with BHA543-551 being most prominent amongst the peptides tested. 
Having identified novel IBV CD8+ T cell epitopes, we determined the conservation of 
two most prominent peptides, BHA543-551 and BNS1266-274, across IBV strains. Both peptides 
were highly conserved (mean conservation of 99% and 98%, respectively) in >14,000 
sequences per segment, spanning both lineages and 77 years of evolution (1940-2017) 
(Supplementary Fig. 3c). While some of the peptides identified by immunopeptidomics 
were highly conserved (>70%) in IAV (n=6 peptides) or in ICV (n=1) (Supplementary Fig. 
3c), these were not immunogenic in the donors tested. 
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 Overall, the immunopeptidomics approach identified 73 previously uncharacterized 
IBV-derived HLA-A*02:01 peptide-ligands, 67 of which were tested for immunogenicity, 
with CD8+ T cell responses being targeted predominantly to BHA543-551, highly conserved 
across IBV, but not IAV or ICV. 
 
Immunodominance of universal A2/PB1413
+ 
over IBV-specific A2/BHA543
+
CD8
+
 T cells 
in IBV infection  
Our data so far identified three conserved HLA-A*02:01-restricted epitopes for IBV: 
the universal A2/PB1413 and two IBV-specific (A2/BHA543-551 and A2/NS1266-274 hereafter 
A2/BHA543 and A2/BNS1266) epitopes. To further understand the role of the universal 
A2/PB1413
+CD8+ T cells in the immunodominance hierarchy following either IAV or IBV 
infection, we established IAV- or IBV-specific CD8+ T cell lines in vitro from PBMC of 
healthy adults (n=11) and assessed tetramer-specific CD8+ T cell responses against IAV 
epitopes (A2/M158-66 (A2/M158), A2/PA46-54 (A2/PA64), A2/PB1413) and IBV epitopes 
(A2/BHA543, A2/BNS1266, A2/PB1413). Consistent with our IFNγ staining (Fig. 1e), 
A2/PB1413-tetramer detected universal A2/PB1413
+CD8+ T cells within both IAV- or IBV-
specific CD8+ T cell lines, although they displayed differential immunodominance 
hierarchies following either IAV and IBV infection (Fig. 2k-m). Within the IAV-specific 
CD8+ T cell lines, the A2/M158-tetramer
+CD8+ T cell population was significantly dominant 
(median of 3.9% tetramer+ of CD8+ T cells; detected in all 11 donors) over the universal 
A2/PB1413
+
 (0.12%; detected in 10/11 donors) and the subdominant A2/PA46
+CD8+ T cells 
(0.05%) populations (Fig. 2l). Conversely, the universal A2/PB1413 epitope within the IBV-
specific T cell lines was immunodominant (0.3%; detected in 8/11 donors) over the IBV-
specific A2/BHA543 (0.11%; detected in 10/11 donors) and A2/BNS1266 epitopes (0.01%) 
(Fig. 2m). These data demonstrate that (i) the universal A2/PB1413 as well as the newly-
identified IBV-specific A2/BHA543 and A2/BNS1266 CD8
+ T cells can be expanded following 
virus stimulation in vitro, and (ii) immunodominance of the universal A2/PB1413 epitope 
depends on the type of influenza infection. 
 
Recruitment of universal A2/PB1413-421
+
CD8
+
 T cells following human IAV and IBV 
infection in vivo 
To evaluate the recruitment and activation of universal A2/PB1413-421
+CD8+ T cells in 
humans during influenza virus infection, we analyzed PBMC samples from 3 different 
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clinical cohorts of PCR-confirmed IAV- or IBV-infected pediatric and adult individuals (Fig. 
3b). Using a tetramer-associated magnetic enrichment (TAME) technique, we readily 
detected influenza-specific CD8+ T cells directly ex vivo in IAV- and IBV-infected pediatric 
and adult patients (Fig.  3a)27, 28, 29. A healthy adult cohort and a cohort of HLA-A*02:01-
positive patients who were hospitalized with a non-influenza respiratory illness (i.e. 
influenza-PCR negative but PCR-positive for other respiratory viruses such as RSV or 
picornavirus) were also analyzed for comparison (Fig.  3b). A2/M158- and A2/PB1413-
specific CD8+ T cells were detected in 100% and 50% of IAV+ individuals (n=16) 
respectively, while A2/BHA543- and A2/PB1413-specific CD8
+ T cells were detected in 75% 
and 87.5% of IBV+ individuals (n=8). The frequency of A2/M158- and A2/PB1413-specific 
CD8+ T cells in the blood were significantly increased (4.3- and 6-fold increase, respectively) 
in IAV-infected patients, as compared to memory CD8+ T cells in healthy donors (Fig.  3c). 
The numbers of A2/BHA543- and A2/PB1413-specific CD8
+ T cells in IBV-infected patients 
increased 2.2- and 2.6-fold, respectively, above the numbers in healthy donors, however these 
did not reach statistical significance, most likely due to the differential age distribution in 
IBV-infected (p=0.0002), but not IAV-infected (p=0.27) patients comparing to healthy 
controls. In the influenza-negative hispitalized cohort, CD8+ T cells for all three specificities 
were in the same range as the healthy donors (Fig.  3c). Notably, tetramer-positive CD8+ T 
cells for all 3 specificities could be detected across all age groups (Fig.  3d). 
Tetramer-positive A2/PB1413
+CD8+, IBV-A2/BHA543
+
 and IAV-A2/M158
+ CD8+ T 
cells detected in IAV- or IBV-infected patients displayed an increase in CD38+/Ki-67+ 
expression (Fig.  3e, Supplementary Fig. 4), which represents an activated/effector 
phenotype during human viral infections30, 31, 32, suggesting their recruitment during human 
influenza virus infection. This was not seen in the influenza-negative cohort, suggesting that 
this activation is specific for acute influenza infection. The expression or upregulation of 
additional activation markers, like HLA-DR and PD-1, was also increased on some 
tetramer+CD8+ T cell populations (Supplementary Fig. 5).  The variability in numbers and 
phenotype between tetramer+CD8+ T cells is likely due to (i) the age range and exposure 
history of the donors, and (ii) varying times of sampling following influenza virus infection, 
both within and between the cohorts (Fig.  3b). Indeed, CD8+  T cell responses after human 
A/H1N1 infection peak within 7 days and then contract rapidly33. Additionally, the 
magnitude and activation status of CD8+ T cells within the circulation can underrepresent 
virus-specific cells at the site of human respiratory virus infections31. 
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These data show that A2/PB1413
+CD8+ T cells are truly universal as they can be 
detected with an activated/effector phenotype in HLA-A*0201-expressing influenza-infected 
patients following either IAV or IBV infection. Additionally, activated/effector CD8+ T cells 
specific for A2/BHA543-551, identified by immunopeptidomics, can be detected during human 
IBV infection, illustrating the power of mass-spectrometry in identifying novel peptide 
ligands. 
 
Detection of tissue-resident memory universal A2/PB1413
+
 CD8
+ T cells in human lungs 
As human memory CD8+ T cells also reside outside the circulation31, we used a rare 
set of human lung samples from deceased HLA-A*0201-expressing organ donors (n=8) to 
assess the presence of universal A2/PB1413
+CD8+ T cells at the site of infection. We also used 
human spleens (n=11), tonsils (n=4) and lymph nodes (n=4) to assess the presence of 
influenza-specific CD8+ T cells in the secondary lymphoid organs (SLOs), where memory 
CD8+ T cells are enriched. CD8+ T cells specific for A2/M158 (4/5), A2/PB1413 (2/5), and 
A2/BHA543 (1/5) were detected within human lung CD8
+ T cells (Fig. 4a). Similarly, CD8+ T 
cells specific for A2/M158 (17/18), A2/PB1413 (6/18), and A2/BHA543 (4/18) were detected 
within human lung CD8+ T cells. Importantly, the majority of A2/PB1413
+ and A2/BHA543 
CD8+ T cells exhibited a tissue-resident memory CD69+CD103+CD45RO+ phenotype in the 
human lung but not in SLOs (Fig. 4b), with central (CD27+CD45RA-) or effector (CD27-
CD45RA-) memory-like phenotype dominating in SLOs (Fig. 4c). This analysis indicates the 
presence of universal A2/PB1413
+ tissue-resident memory CD8+ T cell pools in the human 
lung as well as memory pools in human SLOs.  
 Overall, pools of effector and memory IAV-A2/M158
+, IBV-A2/BHA543
+ and 
universal A2/PB1413
+ CD8+ T cells can be detected directly ex vivo in peripheral blood and 
SLOs of healthy individuals as well tissue-resident IAV-A2/M158-specific and universal 
A2/PB1413-specific CD8
+ T cells memory pools in the human lung. 
 
Longitudinal single-cell RNA sequencing analysis of universal and IBV-specific CD8
+
 T 
cells 
 To further understand recruitment and activation phenotype of universal and novel 
IBV-specific CD8+ T cells at the molecular level during human influenza infection, we used 
single-cell RNA sequencing (scRNAseq) to assess the transcriptome of ex-vivo isolated 
tetramer+CD8+ T cells from rare longitudinal PBMC samples obtained from an IBV-infected 
HLA-A*02:01-expressing individual. Infection with a B/Victoria strain was confirmed by 
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PCR35 (Supplementary Fig. 6a) and serological analysis (Supplementary Fig. 6b). Blood 
samples were obtained at baseline (~3 months prior to infection), d14, 3 months and 1.5 years 
after IBV infection (Fig. 5a). Universal A2/PB1413
+CD8+ T cells were readily detected at 
baseline at 19 tetramer+/106 CD8+ T cells, then increased 19-fold to 367 tetramer+/106 CD8+ T 
cells on d14 after infection and were maintained at a similar level (327 tetramer+/106 CD8+ T 
cells) up to 1.5 years after infection (Fig. 5b). Conversely, A2/BHA543
+CD8+ T cells were 
undetectable at the baseline, suggesting this may have been the first IBV infection for this 
donor, despite a previous immunization against B/Yamagata strains, with an inactivated 
vaccine not eliciting CD8+ T cell responses19. A2/BHA543
+CD8+ T cells increased to 73.4 
tetramer+/106 CD8+ T cells on d14 after infection, 5-fold lower than universal 
A2/PB1413
+CD8+ T cells, and close to the detection level at 1.5-year time-point. Thus, 
A2/PB1413
+CD8+ T cells were assessed at all time-points, while IBV-specific 
A2/BHA543
+CD8+ T cells were analyzed only on d14.  
A total of 209 tetramer-positive CD8+ T cells were analyzed using scRNAseq, with an 
average of 1201 expressed genes identified per cell. Principal component analysis (PCA) 
revealed clear segregation of A2/PB1413
+CD8+ T cells by time-point but no segregation 
between the two antigenic effector IBV-specificities (universal A2/PB1413
+CD8+ T cells and 
IBV-specific A2/BHA543
+CD8+ T cells) on d14 (Fig. 5c). Notably, differential expression 
analysis identified distinct gene expression signatures across time-points (Fig. 5d). 
Specifically, gene-set enrichment analysis revealed signatures of T cell activation and 
differentiation, cell division, immune cell migration and chemotaxis, which were enriched in 
d14 cells, as compared to those from baseline or 1.5 years (Fig. 5e-f).  
We next analyzed specific expression of genes associated with T cell differentiation, 
activation, cytotoxicity and effector function (Supplementary Fig. 6cd). Importantly, 
effector CD8+ T cells across both IBV-specificities isolated from d14 upregulated genes 
associated with activation (CD74, CD52), cytotoxic molecules (PRF1, GZMB, GZMA, 
GZMK, GNLY, CTSW), cytotoxic receptors (NKG7, KLRK1) and effector cytokines 
(CCL5, CCL4). The expression profiles for some genes associated with differentiation and 
activation were confirmed by flow-cytometry (Supplementary Fig. 6cd).  
Taken together, although these single-cell RNAseq data were obtained from one 
patient naturally-infected with IBV, this experiment provided a rare opportunity to examine 
baseline PBMC samples from a HLA-A*0201-expressing patient prior to the natural IBV 
infection as well as at the acute (d14), short-term memory (3 months) and long-term memory 
(1.5 years) time-points after the infection. Our results provide clear evidence of transcriptome 
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changes associated with differentiation and activation of A2/PB1413
+CD8+ and 
A2/BHA543
+CD8+ T cells during IBV infection. To the best of our knowledge, these are the 
first data on transcriptome changes within tetramer-specific CD8+ T cells at the single cell 
level from the baseline to long-term memory CD8+ T cells in humans. Thus, through the flow 
cytometric analysis of IBV-infected patients (n=8) and longitudinal scRNAseq analysis of an 
naturally infected individual, we demonstrate that A2/PB1413
+CD8+ and A2/BHA543
+CD8+ T 
cells are recruited to the immune response during IBV infection. 
 
Immunodominance of A2/BHA543- and A2/BNS1266-specific CD8
+
 T cells during IBV 
infection of HHD-A2 mice in vivo 
Having shown the recruitment of activated CD8+ T cells directed at the universal (A2/PB1413) 
and novel IBV-specific (A2/BHA543)
 epitopes during influenza disease in humans, we 
subsequently set to investigate their protective efficacy, especially as the role of CD8+ T cells 
in IBV infection remains unknown. To achieve this, we utilized our previously published 
HHD HLA-A2.1-expressing transgenic (HHD-A2) mouse model of influenza A infection36 
and established a HHD-A2 mouse model of influenza B and influenza C infection. HHD-A2 
mice express a chimeric MHC-I monochain comprising of the human β2-microglobulin 
covalently linked to the HLA-A*02:01 α1 and α2 domains and the murine α3 and 
transmembrane domains37 and thus can respond to many human HLA-A*0201-restricted 
epitopes, including IAV-derived A2/M51
36 or cancer-derived A2/WT1A neoantigen38. These 
mice are not confounded by exposure infection history nor co-expression of other MHC-I 
molecules and thus provide an important model for both understanding influenza-specific 
CD8+ T cell responses in vivo as well as determining their protective role in influenza 
disease.  
Firstly, to verify the immunogenicity of novel IBV-derived peptides, we infected 
HHD-A2 mice intranasally (i.n.) with 100pfu of B/Malaysia virus. On day (d) 10 after 
infection (Fig. 6a), we stimulated splenocytes with each peptide individually (out of 67 
immunoproteomics-derived peptides) and measured production of IFNγ and ΤΝF. As in 
humans (Fig. 2j), immunodominant CD8+ T cell responses were largely targeted towards 
A2/BHA543-551 (mean of 5% of CD8
+ T cells) and A2/BNS1266-274 (mean of 1.8% of CD8
+ T 
cells), with smaller subdominant responses observed for A2/HA538-551 and A2/BNS1264-274 
(mean of <0.5% of CD8+ T cells), which overlap with A2/BHA543-551 and A2/BNS1266-274, 
respectively (Fig. 6b-d). We also assayed the peptides in 6 pools of 10-12 peptides, as for 
human studies (Supplementary Table S2) and assessed CD8+ T cell responses to each pool 
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at the site of infection represented by the bronchoalveolar lavage (BAL). CD8+ T cell 
responses were targeted to pools 2 and 3 (Fig. 6d), containing the BHA543-551, BNS1266-274 
and BNS1264-274 peptides, as confirmed separately (Fig. 6c).  
To compare these primary CD8+ T cells directed at BHA543-551 and BNS1266-274 
epitopes with secondary CD8+ T cell responses, we firstly primed HHD-A2 mice i.n. with 
B/Malaysia, and then i.n. infected with the heterologous strain B/Phuket 6 weeks later 
(Supplementary Fig. 7bc). Assessment of CD8+ T cell responses against the main 
A2/BHA543-551 and A2/BNS1266-274 epitopes in the spleen on d8 after challenge showed that 
the number of secondary IFNγ+TNF+ CD8+ T cells in the spleen was ~27-fold higher than 
following a primary infection (Supplementary Fig. 7bc). Additionally, CD8+ T cells for 
both specificities showed increased polyfunctionality (IFNγ+TNF+IL-2+) following secondary 
infection (0.14% and 2.14% of CD8+ T cells for BHA543, n=4-5, p=0.013) (Supplementary 
Fig. 7d). Thus, using our model of IBV infection in HHD-A2 mice, we verified the novel 
(identified by immunopeptidomics) immunodominant IBV-specific A2/BHA543-551 and 
A2/BNS1266-274 epitopes in both primary and secondary IBV infections. 
 
Lack of A2/PB1413
+
CD8
+
 T cells in HHD-A2 mice 
As universal A2/PB1413
+CD8+ T cells can be readily detected in both IAV- and IBV-
infected patients, we next assessed A2/PB1413
+CD8+ T cell responses following IAV 
(A/X31), IBV (B/Malaysia) or ICV (C/Perth) infection of HHD-A2 mice. Unexpectedly, 
CD8+ T cells specific for the A2/PB1413 epitope could not be detected following either (i) 
primary IAV, IBV or ICV infection (Supplementary Fig. 8a), (ii) secondary infection with 
either a heterologous virus (eg. A/X31àA/PR8) or a heterotypic virus (eg. A/X31àB/Mal) 
in all 4 possible combinations (AàA, AàB, BàB, BàA) (Supplementary Fig. 8b), or 
(iii) tertiary (AàBàA, BàAàB) (Supplementary Fig. 8c) influenza infections (detailed 
description in Supplementary Results).  Additionally, A2/PB1413
+CD8+ T cells in HHD-A2 
mice could not be detected following well-established lipopeptide vaccination 
(Supplementary Fig. 8d) or peptide vaccination (Supplementary Fig. 8f) as well as using 
tetramer-enrichment in naïve mice. Thus, all of these above experiments (Supplementary 
Fig. 8) provide strong evidence for a lack of naïve A2/PB1413-specific precursors in HHD-A2 
mice, most likely due to a TCR repertoire hole in HHD-A2 mice towards the A2/PB1413 
epitope. Hence, the protective role of universal A2/PB1413
+CD8+ T cells towards IAV, IBV 
and ICV infection in vivo could not be assessed in HHD-A2 mice (Supplementary Results).  
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Protective capacity of A2/BHA543- and A2/BNS1266-specific CD8
+
 T cells during in vivo 
infection of HHD-A2 mice 
 Previous studies using CD8+ T cells depletion in mice lacking antibodies have 
demonstrated a role for CD8+ T cells during IBV infection 39. To determine the protective 
capacity of the novel IBV-derived CD8+ T cell epitopes in HHD-A2 mice, we vaccinated 
mice with the BHA543 and BNS1266 peptides using a well-established prime/boost approach, 
then infected mice i.n. with 5x103 pfu B/Malaysia (Fig. 7a). On day 6 after boosting and 
prior to vaccination, no differences in the number of innate cells (neutrophils, macrophages 
or γδ Tcells) were observed between the mock (adjuvant alone) and peptide/adjuvant-
vaccinated groups in blood (data not shown). Thus, any non-specific inflammatory or innate 
effects of vaccination are controlled for in the mock group. 
Vaccination with peptides resulted in significantly higher numbers of total 
A2/BHA543- and A2/BNS1266-tetramer
+CD8+ T cells in the spleen on d6 and d7 after IBV 
infection when compared to mock-vaccinated (adjuvant alone) mice (~5.6-fold p<0.05) (Fig. 
7bc). A2/BHA543
+CD8+ and A2/BNS1266
+CD8+ T cell numbers were comparable (p>0.05) in 
the BAL (with ~2-fold increase in immunized mice). Following immunization, however, 
there was an increase in recruitment of immunodominant A2/BHA543
+CD8+ T cells to the site 
of infection between d6 and d7.  
Importantly, peptide-vaccinated mice exhibited significant protection against IBV, as 
shown by a significant ~65% reduction in viral titers in the lung and nose on d6 and 100% 
clearance in the lung on d7 after IBV infection when compared to the mock-immunized 
group (p<0.05) (Fig. 7d). Additionally, there was a significant decrease (p<0.05) in the levels 
of inflammatory cytokines (MIP-1β, IL-6, IL-1β, IFNγ) in d7 BAL of peptide-vaccinated 
mice in comparison to the mock-immunised animals (Fig. 7ef). Thus, CD8+ T cells directed 
at our novel HLA-A2.1-restricted IBV-specific epitopes are protective, as they can markedly 
accelerate viral clearance and reduce the cytokine storm at the site of infection.  
 
 
DISCUSSION  
Cytotoxic CD8+ T cells play a crucial role in protection from severe influenza disease 
in both human settings and animal models of influenza virus infection1, 2. CD8+ T cells limit 
viral replication and promote clearance of infected cells, the recognition of which is 
dependent on presentation of viral peptides on the cell surface by MHC-I molecules. The 
high conservation of these peptides allows cross-recognition of cells infected by distinct IAV 
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strains, including pandemic and avian IAV viruses1, 2. Our study proposes and examines two 
levels of cross-reactivity by influenza-specific CD8+ T cells: i) heterotypic cross-reactivity 
across IAV and IBV, and in some instances ICV, by CD8+ T cells recognizing peptides 
derived from the most conserved regions of influenza viruses, and ii) IBV-wide cross-
reactivity by CD8+ T cells recognizing peptides derived from highly conserved regions of 
IBV (like BHA543 and BNS1266).  
Broadly-neutralizing antibodies (bNAbs) against the IAV and/or IBV HA stem have 
been the focus of the recent research. However, so far, such broadly cross-reactive antibodies 
have been rare and immuno-subdominant compared to strain-specific antibodies against the 
antigenically variable HA head7. Thus, combining such bNAbs with broadly cross-reactive 
and abundant (at the population level) CD8+ T cells is important for optimal universal 
protection against distinct influenza strains and subtypes. Cross-reactivity across IAV and 
IBV is unprecedented for CD8+ T cells and atypical for influenza-specific CD4+ T cells and 
antibodies. Indeed, only one rare antibody (CR9114) that cross-recognizes a conserved region 
of the IAV and IBV HA stem regions has been identified8 and its contribution in the immune 
response during human infection is unknown. Similarly, a highly conserved CD4+ T cell 
epitope containing a peptide from the fusion peptide of the HA has been identified but 
remains poorly characterized40. Universal memory A2/PB1413 CD8
+ T cells, however, are 
prominent in human peripheral blood and lung tissues and emerge as activated effector cells 
during both human IAV and IBV infections. Additionally, such CD8+ T cells were found in 
the majority (80%) of donors tested, suggesting that such T cell responses are abundant 
across HLA-A*0201+ donors. The heterotypic cross-reactivity demonstrated by our study is 
currently restricted to HLA-A*02:01, A*01:01 and B*37:01, which cover ~54% of the 
world’s population. However, certain ethnic groups would not be sufficiently covered by 
these HLA alleles. Thus, while our study demonstrates the potential of heterotypic cross-
reactivity by CD8+ T cells, it also highlights the need for further identification of universal 
CD8+ T cell epitopes across additional HLA alleles. The advent of immunopeptidomics, the 
unbiased identification of HLA-bound viral peptides using mass spectrometry, could 
facilitate such epitope-discovery endeavors.  
The IBV-wide cross-reactivity resembles that of IAV-wide cross-reactivity provided 
by well-characterized CD8+ T cell specificities, exemplified by A2/M158
36 but also other 
epitopes12, 16. While, the ability of CD8+ T cells to cross-react across the two IBV lineages 
was previously reported11, the antigenic specificity underpinning such cross-reactivity has 
been unknown. We demonstrate that CD8+ T cells target peptides from the BHA and BNS1 
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proteins and that these responses are protective, as they accelerate viral clearance and reduce 
inflammatory cytokines in a murine model of human IBV infection. The observation that 
IBV-wide cross-reactivity can be conferred by peptides derived from the external HA protein 
is intriguing as it contests the belief that CD8+ T cell cross-reactivity is conferred by peptides 
from the internal proteins of influenza viruses and contrasts the known immunodominance of 
responses to M1/NP-derived epitopes from IAV. Whether this is unique to the context of 
HLA-A2 or common across many HLA alleles during IBV responses is currently unknown, 
although an immunodominant epitope with a BHA peptide was also recently identified for 
murine H2-Kd  41. Additionally, IBV-specific CD4+ T cells predominantly recognize peptides 
from the BHA protein, as opposed to M1 and NP for IAV42. Given the high prevalence of 
HLA-A*02:01 and the clinical significance of IBV, our work implies that CD8+ T cell-
targeting vaccines need to be formulated with broader antigenic specificity not limited to NP 
and M1 antigens. 
In our study, we provide direct evidence for the role of CD8+ T cells in protection 
against influenza B viruses. This was demonstrated by immunization with the newly-
identified IBV peptides (BHA543 and BNS1266). Following IBV infection, peptide-immunized 
mice displayed milder influenza disease as shown by significant reductions in both viral titers 
and cytokine storm, when compared to the mock-immunized group. Unexpectedly, 
irrespective of the infection or immunization protocol used, A2/PB1413
+CD8+ T cells could 
not be detected in HHD-A2 mice. This strongly indicated that HHD-A2 mice lack naïve 
A2/PB1413
+CD8+ T cells TCR precursors, most likely as a result of a TCR repertoire hole in 
these mice. This lack of A2/PB1413
+CD8+ T cell responses in HHD-A2 mice is consistent 
with previous studies in HHD-A2/DRB1 mice43. While HHD-A2 mice express a chimeric 
MHC-I monochain comprising of the human β2-microglobulin covalently linked to the HLA-
A*02:01 α1 and α2 domains and the murine α3 and transmembrane domains, T cell receptors 
remain murine. As a result, although HHD-A2.1-expressing mice respond to several human 
HLA-A*0201-restricted epitopes 36, 38, 44 TCRs for others may be lacking. Thus, while these 
mice are a useful tool for screening peptide libraries, results obtained from such screens 
warrant validation using human samples. This mouse model is however, an important tool in 
assessing the protective capacity of antiviral HLA-A2-restriced CD8+ T cells in vivo.  Indeed, 
by vaccinating HHD-A2 mice and challenging them with IBV, we provide the first evidence 
for a protective role of epitope-specific CD8+ T cells in IBV infection following peptide 
vaccination, consistent with CD8+ T cell depletion studies in mice lacking B cells 39. In 
conjunction with the activation of these CD8+ T cells in human patients and the presence of 
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TRM cells in the human lung, these studies suggest that vaccinating against these epitopes 
may provide protection in humans.  
The antigenic origin of such broadly cross-reactive epitopes is also of interest. PB1 is 
the most well-conserved protein across IAV and IBV, with ~60% amino acid identity, as 
opposed to 30% or less for the other proteins4, 24, 45. The PB1413 peptide is derived from one 
of the most well conserved areas of the protein, namely motif B (residues 406-422 of IAV 
PB1 protein), one of the four core motifs present in viral RNA-dependent polymerases. 
Genome-wide mutational analysis, has shown that IAV cannot tolerate substitutions in these 
motifs46. More interesting, however, is the IBV-wide cross-reactivity conferred by the 
BHA543 peptide.  This peptide is derived from the stalk region of the BHA molecule, which 
shows considerably higher conservation than the HA head domain47. Mutagenesis screens in 
vitro have also revealed limited tolerance to 15-nucleotide insertions of in the BHA molecule, 
particularly the stalk domain47. Thus, these universally cross-reactive CD8+ T cells target 
epitopes with little sequence flexibility, making them ideal targets for a universal as well as 
IBV-wide influenza vaccine. Such extensive cross-reactivity across virus genera is 
uncommon and only resembles that of CD8+ and CD4+ T cells across the subfamily of 
Alphaherpseviruses
48 and to a lesser extend CD8+ T cell cross-reactivity across the Flavivirus 
genus49. 
 Overall, the ability of CD8+ T cells to confer heterotypic cross-reactivity across IAV 
and IBV and the knowledge of cross-reactive epitopes across IAV/IBV types as well as 
within IBV strains, have substantial implications for the design of universal influenza 
vaccines that do not require annual reformulation. Pre-emptive influenza vaccines eliciting 
broadly-cross-reactive and long-lasting CD8+ T cell immunity would reduce annual rates of 
IAV/IBV-induced morbidity and mortality globally. Additionally, an influenza vaccine 
eliciting immunity across influenza A, B and C viruses could also protect children from 
severe ICV disease5. Furthermore, T cell-targeted vaccines would also augment the numbers 
of universal IAV/IBV/ICV-, IAV- and IBV-specific CD8+ T cell responses in individuals 
with previous influenza virus exposures (as currently these are mostly detectable ex vivo by 
tetramer enrichment in healthy donors) and thus would confer stronger protective immunity 
following infection14. Thus, it is critical to consider universal CD8+ T cells, alongside with 
universal antibodies, for the design of universally cross-reactive influenza vaccines, 
especially as the current inactivated influenza vaccines do not elicit influenza-specific CD8+ 
T cell responses4.    
 
	 19	
ACKNOWLEDGEMENTS 
HLA-A2.1 transgenic HHD mice were developed by Dr François Lemonnier (Pasteur 
Institute, Paris, France). D227K and Q115E MHC-I constructs were developed and provided 
by Prof Linda Wooldridge (Bristol University). The authors acknowledge the provision of 
instrumentation, training and technical support by the Monash Biomedical Proteomics 
Facility. We thank all study participants and organ donors. We are very grateful to the 
coordinators of DonateLife Victoria for obtaining organ tissues, and to Lina 
Mariana and Cameron Kos (St. Vincent’s Institute) for their assistance.  
 
Funding  
The Australian National Health and Medical Research Council (NHMRC) NHMRC Program 
Grant (1071916) to KK supported this work. MK is a recipient of Melbourne International 
Research Scholarship and Melbourne International Fee Remission Scholarship. SS is a 
recipient Victoria India Doctoral Scholarship and Melbourne International Fee Remission 
Scholarship, University of Melbourne. KK is an NHMRC Senior Research Level B Fellow. 
JR is supported by and ARC Laureate fellowship. SG is a Monash Senior Research Fellow. 
FL is a NHMRC CDF2 Fellow. EBC and AAE are NHMRC Peter Doherty Fellows. The 
Melbourne WHO Collaborating Centre for Reference Research on Influenza is supported by 
the Australian Government Department of Health. AWP is supported by an NHMRC 
Principal Research Fellowship (1137739).  And NHMRC Project grant (1085018) to AWP, 
TCK and NAM. AC is a NHMRC Career Development (level 2) Fellow. DT and DV are 
supported by contract HHSN272201400006C from the National Institute of Allergy and 
Infectious Disease, National Institutes of Health, Department of Health and Human Services, 
USA. PTI was supported by NHMRC Peter Doherty Fellowship (1072159). PGT is 
supported by the St. Jude Center of Excellence for Influenza Research and Surveillance 
(NIAID Contract HHSN27220140006C), R01 AI 107625, R01AI136514, and ALSAC.   
Conflicts of interest 
SR is an employee of Seqirus Ltd and has no conflict of interest in the material presented. 
MK, KK and EBC are named as co-inventors in a patent application filed by the University 
of Melbourne (AU2017903652) covering the use of certain peptides described in the 
publication as part of vaccine formulation. The other authors declare no conflicts of interest. 
 
 
	 20	
Author Contributions  
MK, KK, THON, PI, NAM, AWP, SG, DV, FL and PGT designed experiments. MK, PI, 
THON, NAM, AAE, EBC, SS, CYW, BYC, EKA, PD, LG, WZ and SG performed 
experiments. AH, IB, DCJ, TCK, ACC, MR, GPW, LMW, ST, SM, TL, BD, ME, PGT 
provided reagents and/or samples. MK, PI, THON, JCC, SS, SR, DT, DV, FL SG, JR, PGT, 
AWP and KK analyzed data. MK, THON and KK wrote the manuscript. All authors read and 
approved the manuscript. 
 
 
References 
1. Krammer, F. et al. Influenza. Nat Rev Dis Primers 4, 3 (2018). 
 
2. Nussing, S. et al. Innate and adaptive T cells in influenza disease. Front Med 12, 34-
47 (2018). 
 
3. Paules, C. & Subbarao, K. Influenza. Lancet 390, 697-708 (2017). 
 
4. Koutsakos, M., Nguyen, T.H., Barclay, W.S. & Kedzierska, K. Knowns and 
unknowns of influenza B viruses. Future Microbiol 11, 119-135 (2016). 
 
5. Matsuzaki, Y. et al. Clinical features of influenza C virus infection in children. J 
Infect Dis 193, 1229-1235 (2006). 
 
6. Chen, Y.Q. et al. Influenza Infection in Humans Induces Broadly Cross-Reactive and 
Protective Neuraminidase-Reactive Antibodies. Cell 173, 417-429 e410 (2018). 
 
7. Corti, D. et al. Tackling influenza with broadly neutralizing antibodies. Curr Opin 
Virol 24, 60-69 (2017). 
 
8. Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. 
Science 337, 1343-1348 (2012). 
 
9. Hayward, A.C. et al. Natural T Cell-mediated Protection against Seasonal and 
Pandemic Influenza. Results of the Flu Watch Cohort Study. Am J Respir Crit Care 
Med 191, 1422-1431 (2015). 
 
10. McMichael, A.J., Gotch, F.M., Noble, G.R. & Beare, P.A. Cytotoxic T-cell immunity 
to influenza. . New Eng J Med 309, 13-17 (1983). 
 
11. van de Sandt, C.E. et al. Influenza B virus-specific CD8+ T-lymphocytes strongly 
cross-react with viruses of the opposing influenza B lineage. J Gen Virol 96, 2061-
2073 (2015). 
 
	 21	
12. Gras, S. et al. Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-
2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci U S A 107, 12599-
12604 (2010). 
 
13. Greenbaum, J.A. et al. Pre-existing immunity against swine-origin H1N1 influenza 
viruses in the general human population. Proc Natl Acad Sci U S A 106, 20365-20370 
(2009). 
 
14. Quinones-Parra, S.M. et al. A Role of Influenza Virus Exposure History in 
Determining Pandemic Susceptibility and CD8+ T Cell Responses. J Virol 90, 6936-
6947 (2016). 
 
15. Sridhar, S. et al. Cellular immune correlates of protection against symptomatic 
pandemic influenza. Nature medicine 19, 1305-1312 (2013). 
 
16. Quinones-Parra, S. et al. Preexisting CD8+ T-cell immunity to the H7N9 influenza A 
virus varies across ethnicities. Proc Natl Acad Sci U S A 111, 1049-1054 (2014). 
 
17. Wang, Z. et al. Recovery from severe H7N9 disease is associated with diverse 
response mechanisms dominated by CD8(+) T cells. Nat Commun 6, 6833 (2015). 
 
18. Wang, Z. et al. Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during 
fatal H7N9 disease. Nat Commun 9, 824 (2018). 
 
19. Koutsakos, M. et al. Circulating TFH cells, serological memory, and tissue 
compartmentalization shape human influenza-specific B cell immunity. Sci Transl 
Med 10 (2018). 
 
20. Ramarathinam, S.H. et al. Identification of Native and Posttranslationally Modified 
HLA-B*57:01-Restricted HIV Envelope Derived Epitopes Using Immunoproteomics. 
Proteomics 18, e1700253 (2018). 
 
21. Williamson, N.A. & Purcell, A.W. Use of proteomics to define targets of T-cell 
immunity. Expert Rev Proteomics 2, 367-380 (2005). 
 
22. Alexander, J. et al. Identification of broad binding class I HLA supertype epitopes to 
provide universal coverage of influenza A virus. Hum Immunol 71, 468-474 (2010). 
 
23. Rosendahl Huber, S.K. et al. Chemical Modification of Influenza CD8+ T-Cell 
Epitopes Enhances Their Immunogenicity Regardless of Immunodominance. PLoS 
One 11, e0156462 (2016). 
 
24. Terajima, M., Babon, J.A., Co, M.D. & Ennis, F.A. Cross-reactive human B cell and 
T cell epitopes between influenza A and B viruses. Virol J 10, 244 (2013). 
 
25. Zemmour, J., Little, A.M., Schendel, D.J. & Parham, P. The HLA-A,B "negative" 
mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point 
mutation in the translation initiation codon. J Immunol 148, 1941-1948 (1992). 
 
	 22	
26. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H.G. Allele-specific 
motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 
351, 290-296 (1991). 
 
27. Alanio, C., Lemaitre, F., Law, H.K., Hasan, M. & Albert, M.L. Enumeration of 
human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. 
Blood 115, 3718-3725 (2010). 
 
28. Moon, J.J. et al. Naive CD4(+) T cell frequency varies for different epitopes and 
predicts repertoire diversity and response magnitude. Immunity 27, 203-213 (2007). 
 
29. Nguyen, T.H.O. et al. Perturbed CD8(+) T cell immunity across universal influenza 
epitopes in the elderly. J Leukoc Biol 103, 321-339 (2018). 
 
30. Chandele, A. et al. Characterization of Human CD8 T Cell Responses in Dengue 
Virus-Infected Patients from India. J Virol 90, 11259-11278 (2016). 
 
31. Jozwik, A. et al. RSV-specific airway resident memory CD8+ T cells and differential 
disease severity after experimental human infection. Nat Commun 6, 10224 (2015). 
 
32. Miller, J.D. et al. Human effector and memory CD8+ T cell responses to smallpox 
and yellow fever vaccines. Immunity 28, 710-722 (2008). 
 
33. Hillaire, M.L. et al. Characterization of the human CD8(+) T cell response following 
infection with 2009 pandemic influenza H1N1 virus. J Virol 85, 12057-12061 (2011). 
 
34. Sathaliyawala, T. et al. Distribution and compartmentalization of human circulating 
and tissue-resident memory T cell subsets. Immunity 38, 187-197 (2013). 
 
35. Allen, R.J., Koutsakos, M., Hurt, A.C. & Kedzierska, K. Uncomplicated Cystitis in an 
Adult Male Following Influenza B Virus Infection. Am J Case Rep 18, 190-193 
(2017). 
 
36. Valkenburg, S.A. et al. Molecular basis for universal HLA-A*0201-restricted CD8+ 
T-cell immunity against influenza viruses. Proc Natl Acad Sci U S A 113, 4440-4445 
(2016). 
 
37. Pascolo, S. et al. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T 
lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-
2Db beta2m double knockout mice. J Exp Med 185, 2043-2051 (1997). 
 
38. Nguyen, T.H. et al. Understanding CD8(+) T-cell responses toward the native and 
alternate HLA-A*02:01-restricted WT1 epitope. Clin Transl Immunology 6, e134 
(2017). 
 
39. Epstein, S.L., Lo, C.Y., Misplon, J.A. & Bennink, J.R. Mechanism of protective 
immunity against influenza virus infection in mice without antibodies. J Immunol 
160, 322-327 (1998). 
 
	 23	
40. Babon, J.A., Cruz, J., Ennis, F.A., Yin, L. & Terajima, M. A human CD4+ T cell 
epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes 
and to influenza B virus. J Virol 86, 9233-9243 (2012). 
 
41. Muralidharan, A. et al. Identification of immunodominant CD8 epitope in the stalk 
domain of influenza B viral hemagglutinin. Biochem Biophys Res Commun 502, 226-
231 (2018). 
 
42. Richards, K.A., Treanor, J.J., Nayak, J.L. & Sant, A.J. Overarching 
Immunodominance Patterns and Substantial Diversity in Specificity and Functionality 
in the Circulating Human Influenza A and B CD4 T Cell Repertoire. J Infect Dis 
(2018). 
 
43. Pedersen, S.R. et al. Immunogenicity of HLA Class I and II Double Restricted 
Influenza A-Derived Peptides. PLoS One 11, e0145629 (2016). 
 
44. Tan, A.C. et al. The design and proof of concept for a CD8(+) T cell-based vaccine 
inducing cross-subtype protection against influenza A virus. Immunol Cell Biol 91, 
96-104 (2013). 
 
45. Jackson, D., Elderfield, R.A. & Barclay, W.S. Molecular studies of influenza B virus 
in the reverse genetics era. J Gen Virol 92, 1-17 (2011). 
 
46. Wang, L. et al. Functional Genomics Reveals Linkers Critical for Influenza Virus 
Polymerase. J Virol 90, 2938-2947 (2015). 
 
47. Fulton, B.O., Sun, W., Heaton, N.S. & Palese, P. The influenza B virus hemagglutinin 
head domain is less tolerant to transposon mutagenesis than that of the influenza A 
virus. J Virol (2018). 
 
48. Jing, L. et al. Extensive CD4 and CD8 T Cell Cross-Reactivity between 
Alphaherpesviruses. J Immunol 196, 2205-2218 (2016). 
 
49. Lima, N.S., Rolland, M., Modjarrad, K. & Trautmann, L. T Cell Immunity and Zika 
Virus Vaccine Development. Trends Immunol 38, 594-605 (2017). 
 
 
 
 
FIGURE LEGENDS 
 
Figure 1.  CD8
+
 T cell cross-reactivity across influenza A, B and C viruses. (a) 
Conservation of known IAV epitopes in IBV and ICV. The bars indicate the percent 
conservation (average amino acid identity) of each peptide across the three types of viruses in 
the indicated number of sequences. (b) Highly conserved peptides across IAV, IBV and ICV 
types were selected for dissection of cross-reactive CD8+ T cell responses. (c) 
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Immunogenicity of memory CD8+ T cells directed at conserved peptides in healthy adults. 
PBMCs were cultured with the peptides (as outlined in B) for ~10 days and responses were 
assessed in an IFN-γ ICS. Frequency of IFNγ+CD8+ T cells after subtracting ‘no peptide’ 
control and responding donors are shown. Dots indicate individual donors, median and 
interquartile range (IQR) shown.  (n=3-5). (d) Conservation of PB1413-421 in 
Orthomyxoviruses. Alignment of PB1 sequences derived from viruses representing each 
genus is shown. The box indicates the PB1413-421 peptide. (e) A2/PB1413-421-mediated cross-
reactivity across IAV, IBV and ICV. PBMCs were stimulated with either virus for ~10 days 
and responses to the peptide were assessed in an ICS. A2/PB1413-421
+CD8+ T cell responses 
measured directly ex-vivo by ICS are shown for comparison. Representative concatenated 
FACS plots for IFNγ production are shown. Data points indicate individual donors, median 
and IQR. (n=6). Statistical significance was determined using the Mann-Whitney test, 
*p<0.05, **p<0.005. (f) B37/NP338-345-mediated and (g) A1/PB1591-599-mediated cross-
reactivity across IAV and IBV. On ~day10 of peptide culture, CD8+ T cell responses to either 
IAV or IBV variants were assessed by ICS. Dots indicate individual donors and bars indicate 
the mean (n=3-4). (e-f) ‘No peptide’ control was subtracted. 
 
Figure 2. Identification of novel protective IBV CD8
+
 T cell epitopes by 
immunopeptidomics. (a) Immunopeptidomics outline. (b) Peptide binding motifs for host 
and IBV HLA-A*02:01 ligands generated from combined non-redundant lists of 9mer, 
10mer and 11mer, using Icelogo by the static reference method against the swiss-prot human 
proteome. (c) Length distribution of filtered HLA-A*02:01 ligands (non-redundant by 
sequence) from uninfected (single experiment) and B/Malaysia infected (2 experiments) 
CIR.A*02:01 cells. Numbers of peptides of each length identified from the Human proteome 
(5% FDR cut-off) and B/Malaysia proteome (all confidences) are shown. (d) Distribution of 
IBV-derived HLA ligands (non-redundant by sequence) across the B/Malaysia proteome, 
identified as likely HLA-A*02:01 ligands. Pooled data from 2 independent experiments. (e-
h) In vitro screening of novel peptides in human HLA-A*02:01-expressing PBMCs. (e) 
Experimental outline of screening. (f) Representative concatenated FACS plots for each 
peptide pool are shown, with a mock (unstimulated) control outlined for comparison. 
Frequency of IFNγ+TNF+CD8+ T cells for each pool. Dots indicate individual donors, median 
and IQR are shown (n=11). (g) Frequncy of responding donors for each pool (n=11). (h) 
Frequency of IFNγ+TNF+CD8+ T cells directed towards individual peptides from pool 2 
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(n=6), median and IQR are shown. (i-j) In vitro validation of immunogenic peptides. (i) 
Experimental outline of validation. (j) Representative FACS plots for a positive CD8+ T cell 
response directed towards each peptide. Frequency of IFNγ+TNF+CD8+ T cells. Donors are 
color-coded, medians and IQRs are shown. (n=6). (k-m) Immunodominance of universal 
CD8+ T cells during in vitro IAV or IBV infection. (k) Experimental outline. (l) Responses 
during IAV infection against A2/M158, A2/PA46 and A2/PB1413 and (m) during IBV infection 
against A2/BHA543, A2/BNS1266 and A2/PB1413. Bar charts show the contribution of each 
specificity to the total measured (sum of tetramer+) response. ND: not detected. 
 
Figure 3. Prominance of memory and effector pools of universal CD8
+
 T cells in healthy 
adults, influenza-infected individuals and human tissues. (a-d) Tetramer-specific CD8+ T 
cells in healthy and influenza-infected individuals. (a) Ex-vivo TAME on PBMCs from 
healthy and infected donors. Representative FACS plots are shown. (b) Characteristics of 
healthy and influenza-infected or influenza-negative ILI cohorts used in this study. ILI: 
influenza-like illness. (c) Precursor frequency of tetramer+ cells in healthy, influenza-infected 
individuals  and influenza-negative ILI patients (n=6-24). Statistical significance was 
determined using the Mann-Whitney test, *p<0.05, **p<0.005. Median and IQR are shown. 
(d) Precursor frequency of tetramer+ CD8+ T cells in healthy and influenza-infected 
individuals across age. (e) Expression profiles of tetramer+ CD8+ T cells for 
activation/effector markers CD38 and Ki-67. Representative FACS plots are shown. 
Frequency of CD38+/Ki-67+ tetramer+ CD8+ T cells from healthy controls (n=3-5) and 
influenza-infected donors (n=6-26). Statistical significance for changes in the frequency of 
CD38-Ki-67- cells was determined using the Mann-Whitney test A, *p<0.05, **p<0.005. 
 
Figure 4. Universal CD8
+
 T cells with a tissue-resident phenotype in the human lung. (a) 
Ex-vivo detection of universal CD8+ T cells in human lung and secondary lymphoid organ 
(spleen, tonsils and lymph nodes) samples. Frequency of tetramer+ CD8+ T cells (n=8 lungs, 
n=11 spleens, n=4 tonsils, n=4 lymph nodes). (b) Phenotype of tetramer+ CD8+ T cells based 
on CD103 and CD69 expression. (c) Phenotype of tetramer+ CD8+ T cells based on CD27 
and CD645RA expression.  Representative FACS plots are shown. SLO: secondary lymphoid 
organs.  
 
Figure 5. Single-cell RNA sequencing of universal CD8
+
 T cells in an IBV-infected 
individual. (a) Timeline of infection and number of tetramer+CD8+ T cells isolated from 
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each sample. (b) FACS plots and precursor frequency of tetramer+ CD8+ T cells prior to, 
during and after IBV infection. (c) Principal component analysis (PCA) of tetramer+ CD8+ T 
cells sequenced. Timepoints are distinguished by colour and specificity by shape. 
(d)  Heatmap illustrating expression of differentially expressed genes identified across all the 
timepoints compared to the baseline as reference using MAST. Cells grouped by epitope and 
timepoint. (e) Heatmap representing the gene sets enrichment of up-regulated (pink) and 
down-regulated (green) genes of tetramer+CD8+ T cells sorted at d14 compared to baseline. 
(f) Heatmap representing the gene set enrichment of up-regulated (pink) and down-regulated 
(green) genes of tetramer+CD8+ T cells sorted at d14 compared to 1.5-year time-point. 
 
Figure 6. In vivo CD8
+
 T cell responses to novel IBV peptides in HHD (A2
+
) mice. (a) 
Experimental outline of screening. (b) Representative FACS plots for immunogenic peptides. 
(c) Frequency of IFNγ+TNF+CD8+ T cells in the spleen of IBV-infected mice towards each 
peptide. Mean and SEM are shown (n=4-12). (d-e) CD8+ T cell responses in the BAL. (d) 
Cytokine responses to each peptide pool. Data from two independent experiments in which 
the BAL of multiple (n=3-5) mice were pooled. (e) Cytokine responses to individual 
immunogenic peptides in the BAL (n=4). Mean and SEM are shown. 
 
Figure 7. CD8
+
 T cells against novel epitopes mediated protection from IBV challenge.  
(a) Detailed experimental plan of vaccination. (b-d) Tetramer-specific CD8+ T cells 
responses on day 6 and 7 after infection in BAL and spleen; (b) representative FACS plots; 
(c) number of total (A2/BHA543 and A2/BNS1266) tetramer
+ CD8 T cells in the spleen on day 
7 after IBV infection. (d) number of individual A2/BHA543
+ and A2/BNS1266
+ tetramer+ CD8 
T cells in the spleen on day 7 after IBV infection. (e) Viral titers in the lungs and nose of 
peptide-vaccinated and mock-vaccinated mice, following IBV infection. Days 5 (n=5) and d6 
(n=5) were assessed in an independent experiment to d7 (n=4-5). (e-g) Cytokine responses in 
the BAL on d7 after IBV challenge (n=4-5). Means and SEM are shown (n=5). Statistical 
significance was determined using an unpaired t-test. *p<0.05, **p<0.005. ****p<0.0001. 
 
 
